Lv11
30 积分 2023-10-20 加入
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
3小时前
已完结
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
4小时前
已完结
Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation
皖公网安备34019202002308
